Supportive care

Filgrastim versus TBO-filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question. Trifilio S et al. Clin Transplant. 2015 Oct 22. doi: 10.1111/ctr.12637. [Epub ahead of print]. Surgery for vertebral involvement in Multiple Myeloma. Donnarumma P et al. J Neurosurg Sci. 2015 Oct 16. [Epub ahead of print]. Effectiveness of Haemodiafiltration…

Complications of myeloma and its treatments

Endobronchial plasmacytoma in patient with multiple myeloma. Sunnetcioglu A et al. Clin Respir J. 2015 Oct 27. doi: 10.1111/crj.12408. [Epub ahead of print]. Rapid Progression of Vascular and Soft Tissue Calcification while Being Managed for Severe and Persistent Hypocalcemia Induced by Denosumab Treatment in a Patient with Multiple Myeloma and Chronic Kidney Disease. Ueki K et al. Intern Med. 2015;54(20):2637-42. doi: 10.2169/internalmedicine.54.4946. Epub 2015…

Current treatments

Sequential versus alternating administration of VMP and Rd in elderly patients with newly diagnosed MM. Mateos MV et al. Blood. 2015 Oct 23. pii: blood-2015-08-666537. [Epub ahead of print]. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Cavo M et al. Leukemia. 2015 Oct 7. doi: 10.1038/leu.2015.274. [Epub ahead of print].…

General

Myeloma escape from immunity: an “inside” job. Rapoport AP. Blood. 2015 Sep 17;126(12):1401-3. doi: 10.1182/blood-2015-07-659490. Antibody based immunotherapy for multiple myeloma: It’s about time. Sher T et al, Leuk Lymphoma. 2015 Sep 16:1-17. [Epub ahead of print]. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. Karp Leaf R et al. Curr Hematol Malig Rep. 2015 Sep 4. [Epub ahead of…

Complications of myeloma and its treatments

Early Surgical Occipito-Cervical Stabilization for Plasma Cell Neoplasms at the Cranio-Cervical Junction – Systematic Review and Proposal of a Treatment Algorithm. Ahmadi SA et al. Spine J. 2015 Sep 24. pii: S1529-9430(15)01442-4. doi: 10.1016/j.spinee.2015.09.032. [Epub ahead of print]. Pathologic sternal involvement is a potential risk factor for severe sagittal plane deformity in multiple myelomawith concomitant thoracic fractures. Butler JS et…

Current treatments

Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma. Lin TL et al. J Clin Apher. 2015 Sep 5. doi: 10.1002/jca.21421. [Epub ahead of print]. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. Jagirdar N et al. Transfusion. 2015 Sep 2.…